Description

–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–COVID-19-immunoregulation–C98H138N24O33.C2HF3O2—-[1]Ciborowski M, Tomasiak M. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets. Acta Pol Pharm. 2009 May-Jun;66(3):235-42.|[2]Xu Y, Wu W, Wang L, Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro. Blood Coagul Fibrinolysis. 2013 Apr;24(3):332-8.|[3]Rudolph V, Rudolph TK, Schopfer FJ, Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008 Nov;327(2):324-31.|[4]Zhang R, Huang Y, Zhang M, Bivalirudin Utilization in Rats Undergoing Cardiopulmonary Bypass: Preventing the Increase of Antiheparin/Platelet Factor 4 Antibody in Perioperative Period. Clin Appl Thromb Hemost. 2012 Aug 21. [Epub ahead of print]|[5]Gleason TG, Chengelis CP, Jackson CB, A 24-hour continuous infusion study of bivalirudin in the rat. Int J Toxicol. 2003 May-Jun;22(3):195-206.–1191386-55-6–2294.34–99.89–C(C(O)=O)(F)(F)F.C([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC1=CC=CC=C1)NC([C@@H](NC(CNC([C@@H](NC(CNC(CNC(CNC(CNC(=O)[C@H]2N(C([C@@H](NC(=O)[C@H]3N(C([C@@H](CC4=CC=CC=C4)N)=O)CCC3)CCCNC(=N)N)=O)CCC2)=O)=O)=O)=O)CC(N)=O)=O)=O)CC(O)=O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)[C@H](CC)C)(=O)N5[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC6=CC=C(O)C=C6)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCC5–Cardiovascular Disease–DMSO : ≥ 31 mg/mL|H2O : ≥ 50 mg/mL–Thrombin—-Metabolic Enzyme/Protease–Peptides